Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tivozanib - Kyowa Hakko Kirin/AVEO Oncology

Drug Profile

Tivozanib - Kyowa Hakko Kirin/AVEO Oncology

Alternative Names: ASP 4130; AV-951; AVE-951; Fotivda; Kil8951; KRN-951; Tivopath; Tivozanib hydrochloride monohydrate

Latest Information Update: 06 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AVEO Oncology; EUSA Pharma; Institute Gustave-Roussy; Kyowa Hakko Kirin; Northwestern University; Pharmstandard
  • Class Antineoplastics; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Age-related macular degeneration; Renal cell carcinoma

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Soft tissue sarcoma
  • Phase I/II Liver cancer
  • Preclinical Age-related macular degeneration
  • Suspended Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Solid tumours

Most Recent Events

  • 31 Jan 2019 AVEO Oncology accepts US FDA recommendation for delayed submission of NDA for Renal cell carcinoma based on updated efficacy data
  • 12 Dec 2018 AVEO Oncology plans a phase I/II trial for Hepatocellular carcinoma (First-line therapy, Combination therapy) in 2019
  • 10 Dec 2018 Aveo Oncology plans a phase III trial for Renal cell carcinoma (Combination therapy with nivolumab) (Aveo Oncology pipeline, December 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top